SSA
SANA icon

Schonfeld Strategic Advisors’s Sana Biotechnology SANA Stock Holding History

Schonfeld Strategic Advisors’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55,842
Closed -$227K – 2612
2025
Q4 		$227K Buy
+55,842
New +$250K ﹤0.01% 1665
2024
Q3 		– Sell
-105,325
Closed -$575K – 2374
2024
Q2 		$575K Buy
+105,325
New +$839K ﹤0.01% 1431
2024
Q1 		– Sell
-177,000
Closed -$722K – 2358
2023
Q4 		$722K Buy
177,000
+150,164
+560% +$553K ﹤0.01% 1156
2023
Q3 		$104K Buy
+26,836
New +$144K ﹤0.01% 1492
2022
Q4 		– Sell
-134,854
Closed -$809K – 2955
2022
Q3 		$809K Buy
134,854
+117,454
+675% +$848K 0.01% 1426
2022
Q2 		$112K Sell
17,400
-64,000
-79% -$408K ﹤0.01% 2103
2022
Q1 		$672K Buy
+81,400
New +$658K 0.01% 1197

Other funds holding SANA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Schonfeld Strategic Advisors's SANA Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Sana Biotechnology (SANA) in Q1 2026, closing a stake of 55,842 shares — an estimated $227K sold.

Schonfeld Strategic Advisors first reported a position in SANA in Q1 2022 and held it in 7 quarters. The position peaked at $809K in Q3 2022. 203 funds tracked by Wall St. Rank hold SANA as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Sana Biotechnology position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 55,842 Sana Biotechnology shares in Q1 2026, an estimated $227K.
  • Schonfeld Strategic Advisors first reported a position in Sana Biotechnology in Q1 2022 and held it in 7 quarters.
  • Schonfeld Strategic Advisors's Sana Biotechnology position peaked at $809K in Q3 2022.
  • 203 funds tracked by Wall St. Rank held Sana Biotechnology as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.